Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)
The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.
Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.
Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.
Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Marta Ramon Krauel, MD PhD
- Numer telefonu: 71702 +34 932 804 000
- E-mail: marta.ramon@sjd.es
Lokalizacje studiów
-
-
-
Santiago de Compostela, Hiszpania
- Hospital Clínico Universitario de Santiago
-
Kontakt:
- Lidia Castro, MD
- Numer telefonu: +34 981 951 108
- E-mail: lidia.castro.feijoo@sergas.es
-
-
Barcelona
-
Barcelona, Barcelona, Hiszpania, 08950
- Hospital Sant Joan de Déu
-
Kontakt:
- Marta Ramon Krauel, MD PhD
- Numer telefonu: 71702 +34 932 804 000
- E-mail: marta.ramon@sjd.es
-
-
Madrid
-
Madrid, Madrid, Hiszpania
- Hospital Universitario La Paz
-
Kontakt:
- Isabel Casado, MD
- E-mail: isabelgcasado@gmail.com
-
-
Valencia
-
Valencia, Valencia, Hiszpania
- Hospital Universitario y Politécnico La Fe
-
Kontakt:
- Moreno
- E-mail: morenoframac@gva.es
-
-
Zaragoza
-
Zaragoza, Zaragoza, Hiszpania
- Hospital Universitario Miguel Servet
-
Kontakt:
- Labarta, MD
- Numer telefonu: 3476/3475 +34 976 765 500
- E-mail: jilabarta@salud.aragon.es
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.
Opis
Inclusion Criteria:
- Age between 3 and 16 years.
- Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
- Growth hormone treatment approved by the relevant local authorities and institution.
- Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.
Exclusion Criteria:
- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Weekly Long-Acting Growth Hormone
Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation. |
LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Inne nazwy:
|
|
Daily Recombinant Human Growth Hormone
Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation. |
Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Percentage Total Body Fat
Ramy czasowe: Baseline and 12 months
|
Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated. |
Baseline and 12 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Lean Body Mass
Ramy czasowe: Baseline and 12 months
|
Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms. |
Baseline and 12 months
|
|
Change in body mass index standard deviation score (BMI-SDS)
Ramy czasowe: Baseline and 12 months
|
Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables. |
Baseline and 12 months
|
|
Change in height standard deviation score (SDS)
Ramy czasowe: Baseline and 12 months
|
Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables. |
Baseline and 12 months
|
|
Change in Waist Circumference
Ramy czasowe: Baseline and 12 months
|
Change in waist circumference from baseline to 12 months, expressed in centimeters. |
Baseline and 12 months
|
|
Change in Waist-to-Hip Ratio
Ramy czasowe: Baseline and 12 months
|
Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless. |
Baseline and 12 months
|
|
Change in Systolic Blood Pressure
Ramy czasowe: Baseline and 12 months
|
Change in systolic blood pressure from baseline to 12 months, expressed in mmHg. |
Baseline and 12 months
|
|
Change in Diastolic Blood Pressure
Ramy czasowe: Baseline and 12 months
|
Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg. |
Baseline and 12 months
|
|
Change in Fasting Glucose Concentration
Ramy czasowe: Baseline and 12 months
|
Change in fasting blood glucose concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Fasting Insulin Concentration
Ramy czasowe: Baseline and 12 months
|
Change in fasting blood insulin concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in HOMA-IR
Ramy czasowe: Baseline and 12 months
|
Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Total Cholesterol Concentration
Ramy czasowe: Baseline and 12 months
|
Change in total cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in LDL Cholesterol Concentration
Ramy czasowe: Baseline and 12 months
|
Change in LDL cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in HDL Cholesterol Concentration
Ramy czasowe: Baseline and 12 months
|
Change in HDL cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Triglyceride Concentration
Ramy czasowe: Baseline and 12 months
|
Change in Triglyceride concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Change in Carotid Intima-Media Thickness
Ramy czasowe: Baseline and 12 months
|
Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters. |
Baseline and 12 months
|
|
Change in Bone Mineral Density Z-Score
Ramy czasowe: Baseline and 12 months
|
Change in bone mineral density Z-score measured by DXA from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Height Standard Deviation Score
Ramy czasowe: Baseline and 12 months
|
Change in height standard deviation score (height SDS) from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Growth Velocity Standard Deviation Score
Ramy czasowe: Baseline and 12 months
|
Change in growth velocity standard deviation score from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Bone Age Minus Chronological Age
Ramy czasowe: Baseline and 12 months
|
Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas. |
Baseline and 12 months
|
|
Change in IGF-1 standard deviation score
Ramy czasowe: Baseline and 12 months
|
Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months. |
Baseline and 12 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- EOM-17-26
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .